Syros Pharmaceuticals’ blood cancer prospect tamibarotene has failed another study, triggering a default on a loan and wiping ...

Syros Pharmaceuticals’ stock has declined sharply for the second time in the past three months as its lead cancer therapy, ...

Shares of Syros Pharmaceuticals collapsed in premarket trading Wednesday after the biopharmaceutical company's lead asset, tamibarotene, failed in a late-stage study in a rare blood cancer. Syros late ...

JMP Securities analyst Jason Butler downgraded Syros Pharmaceuticals (SYRS) to Market Perform from Outperform without a price target The firm cites the “disappointing results” from the Phase 3 ...

Syros Pharmaceuticals (SYRS – Research Report) received a Hold rating and price target from TD Cowen analyst Phil Nadeau yesterday. The company’s shares closed yesterday at $2.73. Nadeau covers the ...

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the ...

EST Syros Pharmaceuticals (SYRS) trading halted, news pending Published first on TheFly – the ultimate source for real-time, ...

The upcoming Kia Syros will most likely be positioned between Sonet and Seltos, therefore, potentially creating a new segment ...

Kia Motors has officially announced its upcoming compact SUV, the Syros, anticipated to hit the global market in the coming ...

Kia has officially confirmed the name of its upcoming SUV and it is called the Syros in India. The Syros would be the Kia 2.0 ...

After the launch of EV9 flagship electric SUV and Carnival premium MPV, Kia Syros will be the first SUV to launch under 2.0 ...

Shortly after the teaser sketches of the new SUV were revealed, we have now got to know that it will be now called the Kia ...